Verdict91/ 100
Grade A− · #2Eden
A polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenHead-to-head verdict
Eden vs Gala Health
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict86/ 100
Grade B · #7Gala Health
A cheap compounded entry with a real brand-Ozempic path and nationwide coverage — but the $179 is a yearly-subscription rate, and Gala publishes no month-to-month price at all, which is what the verdict now docks it hardest for.
Visit Gala HealthThe verdict
Winner: Eden
Eden takes it with a higher Verdict Score — 91/100 to 86/100 (grade A− vs B). People who prioritize a vetted, high-transparency provider over the lowest sticker price. Gala Health still earns its place — patients in any state willing to commit to a year up front for a low compounded tirzepatide rate, while keeping a legitimate brand-name option on the table.
Neither of these is our overall #1. That title goes to CoreAge Rx (94/100) — the most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
90Real-world results85
90
Real-world results85
89Price honesty87
89
Price honesty87
95Prescriber access88
95
Prescriber access88
86Formulary choice88
86
Formulary choice88
90Cancellation fairness84
90
Cancellation fairness84
92Member support84
92
Member support84
Price, coverage & features
| Metric | Eden | Gala Health |
|---|---|---|
| Verdict Score | 91/100 | 86/100 |
| Grade | A− | B |
| Semaglutide | $239/mo | Not disclosed |
| Tirzepatide | $349/mo | $179/mo (annual) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | No |
Eden
What we like
- High verification confidence — clear supply-chain and clinician disclosure
- Nationwide availability
- Both molecules offered
The caveats
- Premium pricing vs the cheapest tiers
- Compounded only — no brand-name access
- FDA issued a warning letter to Eden Health International Inc. dba Eden in June 2026; it is public in FDA's warning-letter database
Gala Health
What we like
- Low compounded entry at $179/mo — on a yearly subscription — with all doses included, so titrating up costs nothing extra
- Available in all 50 states, so access never blocks the sign-up
- Offers a real FDA-approved brand path (Ozempic) alongside the compounded track, which most compounded-only programs cannot
- Adjacent HRT and menopause care for patients who want more than a GLP-1 alone
The caveats
- The $179 requires a yearly subscription — no month-to-month rate is published, and the cheapest term quoted in prose is $199/mo on a 3-month plan
- The $149 'microdose' tier is sub-therapeutic — a longevity protocol, not a cheaper weight-loss dose
- GLP-1 is compounded, not FDA-approved — the standard verification caveat applies
- Brand Ozempic runs $1,299/mo, and the dispensing pharmacy is never named — vet it yourself
Our pick — visit
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Also worth a look
Patients in any state willing to commit to a year up front for a low compounded tirzepatide rate, while keeping a legitimate brand-name option on the table.
Visit Gala Health Read the full Gala Health review →Keep comparing
Neither of these has to be the answer: the rivals we rank against Eden cover the 7 programs closest to it, and the same shortlist for Gala Health does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.